Monomeric DR2/MOG-35-55 recombinant TCR ligand treats relapses of experimental encephalomyelitis in DR2 transgenic mice

Jason Link, Cathleen M. Rich, Maya Korat, Gregory G. Burrows, Halina Offner, Arthur Vandenbark

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Treatment of human autoimmune diseases such as multiple sclerosis (MS) will likely require agents that can prevent or reverse the inflammatory process that results in clinical relapses and disease progression. We evaluated the ability of a newly designed monomeric recombinant TCR ligand (RTL342M) containing HLA-DR2 peptide-binding domains covalently linked to MOG-35-55 peptide to prevent and treat both the initial episode and subsequent relapses of experimental autoimmune encephalomyelitis (EAE) in HLA-DR2 transgenic mice. Single doses of RTL342M given either i.v. or s.c. to HLA-DR2 mice produced a rapid (within 24 h) and dose-dependent reversal of clinical signs of paralytic EAE, and even a single dose ≤ 2 μg could produce a significant treatment effect. Multiple daily doses were even more effective than the same total amount of RTL given as a single dose. By establishing the minimal effective dose, we determined that RTLs may be 50 times more potent than molar equivalent doses of myelin peptide alone. RTL342M given prior to induction of EAE prevented disease in most mice, and the remainder could be successfully retreated with RTL. Most important for clinical application, RTL342M was highly effective for treating EAE relapses when given periodically prior to the relapse or even after relapses had occurred. These data demonstrate the rapid and potent clinical effects of RTL342M at disease onset and during relapses in EAE and establish important principles governing the application of this novel approach as a possible therapy for patients with MS.

Original languageEnglish (US)
Pages (from-to)95-104
Number of pages10
JournalClinical Immunology
Volume123
Issue number1
DOIs
StatePublished - Apr 2007

Fingerprint

Encephalomyelitis
Autoimmune Experimental Encephalomyelitis
Transgenic Mice
HLA-DR2 Antigen
Ligands
Recurrence
Multiple Sclerosis
Peptides
Myelin Sheath
Autoimmune Diseases
Disease Progression
Therapeutics

Keywords

  • Autoimmunity
  • Experimental autoimmune encephalomyelitis
  • HLA-DR2
  • Minimum effective dose
  • Multiple sclerosis
  • Myelin oligodendrocyte glycoprotein
  • Recombinant TCR ligand

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Monomeric DR2/MOG-35-55 recombinant TCR ligand treats relapses of experimental encephalomyelitis in DR2 transgenic mice. / Link, Jason; Rich, Cathleen M.; Korat, Maya; Burrows, Gregory G.; Offner, Halina; Vandenbark, Arthur.

In: Clinical Immunology, Vol. 123, No. 1, 04.2007, p. 95-104.

Research output: Contribution to journalArticle

@article{f15c64eacfb04093af56d3b6c5a9fc6b,
title = "Monomeric DR2/MOG-35-55 recombinant TCR ligand treats relapses of experimental encephalomyelitis in DR2 transgenic mice",
abstract = "Treatment of human autoimmune diseases such as multiple sclerosis (MS) will likely require agents that can prevent or reverse the inflammatory process that results in clinical relapses and disease progression. We evaluated the ability of a newly designed monomeric recombinant TCR ligand (RTL342M) containing HLA-DR2 peptide-binding domains covalently linked to MOG-35-55 peptide to prevent and treat both the initial episode and subsequent relapses of experimental autoimmune encephalomyelitis (EAE) in HLA-DR2 transgenic mice. Single doses of RTL342M given either i.v. or s.c. to HLA-DR2 mice produced a rapid (within 24 h) and dose-dependent reversal of clinical signs of paralytic EAE, and even a single dose ≤ 2 μg could produce a significant treatment effect. Multiple daily doses were even more effective than the same total amount of RTL given as a single dose. By establishing the minimal effective dose, we determined that RTLs may be 50 times more potent than molar equivalent doses of myelin peptide alone. RTL342M given prior to induction of EAE prevented disease in most mice, and the remainder could be successfully retreated with RTL. Most important for clinical application, RTL342M was highly effective for treating EAE relapses when given periodically prior to the relapse or even after relapses had occurred. These data demonstrate the rapid and potent clinical effects of RTL342M at disease onset and during relapses in EAE and establish important principles governing the application of this novel approach as a possible therapy for patients with MS.",
keywords = "Autoimmunity, Experimental autoimmune encephalomyelitis, HLA-DR2, Minimum effective dose, Multiple sclerosis, Myelin oligodendrocyte glycoprotein, Recombinant TCR ligand",
author = "Jason Link and Rich, {Cathleen M.} and Maya Korat and Burrows, {Gregory G.} and Halina Offner and Arthur Vandenbark",
year = "2007",
month = "4",
doi = "10.1016/j.clim.2006.12.002",
language = "English (US)",
volume = "123",
pages = "95--104",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Monomeric DR2/MOG-35-55 recombinant TCR ligand treats relapses of experimental encephalomyelitis in DR2 transgenic mice

AU - Link, Jason

AU - Rich, Cathleen M.

AU - Korat, Maya

AU - Burrows, Gregory G.

AU - Offner, Halina

AU - Vandenbark, Arthur

PY - 2007/4

Y1 - 2007/4

N2 - Treatment of human autoimmune diseases such as multiple sclerosis (MS) will likely require agents that can prevent or reverse the inflammatory process that results in clinical relapses and disease progression. We evaluated the ability of a newly designed monomeric recombinant TCR ligand (RTL342M) containing HLA-DR2 peptide-binding domains covalently linked to MOG-35-55 peptide to prevent and treat both the initial episode and subsequent relapses of experimental autoimmune encephalomyelitis (EAE) in HLA-DR2 transgenic mice. Single doses of RTL342M given either i.v. or s.c. to HLA-DR2 mice produced a rapid (within 24 h) and dose-dependent reversal of clinical signs of paralytic EAE, and even a single dose ≤ 2 μg could produce a significant treatment effect. Multiple daily doses were even more effective than the same total amount of RTL given as a single dose. By establishing the minimal effective dose, we determined that RTLs may be 50 times more potent than molar equivalent doses of myelin peptide alone. RTL342M given prior to induction of EAE prevented disease in most mice, and the remainder could be successfully retreated with RTL. Most important for clinical application, RTL342M was highly effective for treating EAE relapses when given periodically prior to the relapse or even after relapses had occurred. These data demonstrate the rapid and potent clinical effects of RTL342M at disease onset and during relapses in EAE and establish important principles governing the application of this novel approach as a possible therapy for patients with MS.

AB - Treatment of human autoimmune diseases such as multiple sclerosis (MS) will likely require agents that can prevent or reverse the inflammatory process that results in clinical relapses and disease progression. We evaluated the ability of a newly designed monomeric recombinant TCR ligand (RTL342M) containing HLA-DR2 peptide-binding domains covalently linked to MOG-35-55 peptide to prevent and treat both the initial episode and subsequent relapses of experimental autoimmune encephalomyelitis (EAE) in HLA-DR2 transgenic mice. Single doses of RTL342M given either i.v. or s.c. to HLA-DR2 mice produced a rapid (within 24 h) and dose-dependent reversal of clinical signs of paralytic EAE, and even a single dose ≤ 2 μg could produce a significant treatment effect. Multiple daily doses were even more effective than the same total amount of RTL given as a single dose. By establishing the minimal effective dose, we determined that RTLs may be 50 times more potent than molar equivalent doses of myelin peptide alone. RTL342M given prior to induction of EAE prevented disease in most mice, and the remainder could be successfully retreated with RTL. Most important for clinical application, RTL342M was highly effective for treating EAE relapses when given periodically prior to the relapse or even after relapses had occurred. These data demonstrate the rapid and potent clinical effects of RTL342M at disease onset and during relapses in EAE and establish important principles governing the application of this novel approach as a possible therapy for patients with MS.

KW - Autoimmunity

KW - Experimental autoimmune encephalomyelitis

KW - HLA-DR2

KW - Minimum effective dose

KW - Multiple sclerosis

KW - Myelin oligodendrocyte glycoprotein

KW - Recombinant TCR ligand

UR - http://www.scopus.com/inward/record.url?scp=33947152923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947152923&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2006.12.002

DO - 10.1016/j.clim.2006.12.002

M3 - Article

C2 - 17257899

AN - SCOPUS:33947152923

VL - 123

SP - 95

EP - 104

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 1

ER -